Johnson & Johnson (NYSE:JNJ) Shares Sold by Colton Groome Financial Advisors LLC

Colton Groome Financial Advisors LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 24.4% in the 2nd quarter, Holdings Channel reports. The firm owned 1,615 shares of the company’s stock after selling 520 shares during the period. Colton Groome Financial Advisors LLC’s holdings in Johnson & Johnson were worth $236,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EWA LLC lifted its position in shares of Johnson & Johnson by 20.7% during the second quarter. EWA LLC now owns 1,957 shares of the company’s stock worth $298,000 after purchasing an additional 335 shares in the last quarter. Advisory Resource Group grew its holdings in shares of Johnson & Johnson by 20.2% in the second quarter. Advisory Resource Group now owns 30,096 shares of the company’s stock valued at $4,399,000 after purchasing an additional 5,060 shares in the last quarter. TrueWealth Advisors LLC increased its stake in Johnson & Johnson by 21.5% during the 2nd quarter. TrueWealth Advisors LLC now owns 5,446 shares of the company’s stock worth $796,000 after buying an additional 964 shares during the period. Keynote Financial Services LLC lifted its holdings in Johnson & Johnson by 7.2% during the 2nd quarter. Keynote Financial Services LLC now owns 10,924 shares of the company’s stock worth $1,597,000 after buying an additional 731 shares in the last quarter. Finally, Grove Bank & Trust boosted its position in Johnson & Johnson by 1.5% in the 2nd quarter. Grove Bank & Trust now owns 22,478 shares of the company’s stock valued at $3,285,000 after buying an additional 322 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.1 %

JNJ stock opened at $164.13 on Friday. The stock has a market cap of $395.01 billion, a P/E ratio of 10.23, a PEG ratio of 2.63 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $167.78. The company’s 50 day moving average is $153.92 and its two-hundred day moving average is $153.24.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter last year, the company posted $2.80 earnings per share. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on JNJ shares. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 30th. The Goldman Sachs Group lowered their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Finally, TD Cowen decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.